22 September 2025
22 September 2025
The accelerated approval follows delays and rejections for Stealth Bio’s mitochondria-targeting injection.
The 2024–28 VPAG is the UK's main cost-containment mechanism on National Health Service (NHS) drug spending.
Tryngolza is designed to reduce the production of apoC-III, a protein involved in triglyceride metabolism.
The EU Data Act will shift data control away from manufacturers and large cloud providers to users of connected products and services and smaller EU companies.
The treatment demonstrated sustained efficacy over a two-year follow-up period.
Armed with fresh capital and new leadership, Genetix sharpens its gene therapy focus.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
